Cytosorbents (CTSO) Expected to Announce Earnings on Thursday

Cytosorbents (NASDAQ:CTSO) is expected to post its quarterly earnings results after the market closes on Thursday, March 6th. Analysts expect Cytosorbents to post earnings of ($0.07) per share and revenue of $10.09 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Cytosorbents Price Performance

Shares of NASDAQ:CTSO opened at $1.00 on Wednesday. The company has a market cap of $54.68 million, a price-to-earnings ratio of -2.78 and a beta of 0.61. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The firm has a 50 day simple moving average of $1.04 and a 200 day simple moving average of $1.05. Cytosorbents has a one year low of $0.70 and a one year high of $1.61.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. HC Wainwright reissued a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th. StockNews.com began coverage on shares of Cytosorbents in a research note on Sunday. They set a “hold” rating for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a research note on Tuesday, February 25th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $4.67.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.